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Available online 18 July 2016Background: Pregnancy failure and placenta mediated pregnancy complications affect N25% of pregnancies. Al-
though there is biological plausibility for a procoagulantmechanismunderlying some of these events, antithrom-
botic intervention trials demonstrate limited beneﬁt, possibly through lack of stratiﬁcation in heterogeneous
patient groups. The ANXA5 M2 haplotype is a possible procoagulant biomarker and was tested pragmatically
to determinewhether this screening and LMWH treatment normalized the outcome for ANXA5M2 positive cou-
ples.
Thiswas a pragmatic study that aimed tomeasure the effectiveness of a testing (for theM2haplotype) and treat-
ment (LMWH) pathway in routine clinical practice where there is variation between patients. Such a study in
couples with fertility problems can inform choices between treatments; it is then the management protocol
which is the subject of the investigation, not the individual treatments.
Methods: Couples (N= 77) with one or both partners ANXA5M2 positive demonstrated association of this hap-
lotype with adverse IVF outcome. A pragmatic, multicenter, prospective cohort study of ANXA5 M2 haplotype
screening, and LWMH treatment following embryo transfer (ET) in 103 IVF couples positive for ANXA5 M2
was performed. They were compared with a group of 1000 contemporaneous randomly selected unscreened
and untreated couples undergoing assisted conception, from which 103 matched control couples were derived.
The primary outcome measure was live birth incidence. Secondary outcomes were results following embryo
transfer (ET) and live birth outcome by gender and M2 carriage, and allelic dose inﬂuence.
Findings: The tested and treated cohort of ANXA5 M2 carriers achieved a similar live birth rate (37.9%) per ET
cycle compared to both themore fertile comparison group (38.5%), and to the 103matched controls (33.0%). Sig-
niﬁcantly more treated male carrier only couples had a live birth versus female M2 only (47.7% vs. 25.0% p =
0.045).
Interpretation: Pragmatic ANXA5M5 screening and treatment with LMWH in couples undergoing IVF is associat-
ed with similar outcome to couples with more favorable prognostic factors. The difference in live birth outcome
for treated male only carrier couples may be consistent with an additional maternal thrombophilic factor that
may adversely affect pregnancy, although other mechanisms are possible. This study suggests that LMWH treat-
ment should be started prior to clinical pregnancy..
. This is an op©2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
PMPC
IVF
ANXA5 M2
LMWH
Live birthen access article under1. Introduction
Pregnancy failure and placenta mediated pregnancy complications
(PMPC), miscarriage, fetal growth restriction (FGR), pre-eclampsia
(PE) and abruption, collectively affect over 25% of pregnancies. Fifteenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of women experiencing ≥2 losses, and 1–2% ≥3 losses (Rai and Regan,
2006). With assisted conception, 76.3% of all cycles (that include such
PMPC) do not result in a live birth (Macaldowie et al., 2014). Diagnosis
of PMPC is largely based on clinical outcome rather than cause, despite
heterogeneous disease processes generating the same clinical pregnan-
cy outcome (Greer et al., 2014). The largest single cause of ﬁrst trimester
miscarriage is due to embryo aneuploidy. The remainder are unex-
plained, reﬂecting limited knowledge of implantation and placentation.
The current focus on precision medicine (Collins and Varmus, 2015)
emphasizes the need to stratify PMPC by mechanism, without which
potential therapies may be rejected as ineffective when assessed in a
heterogeneous patient group (Greer et al., 2014). For PMPC there is bi-
ological plausibility for coagulation activation being an underlying
mechanism in a proportion of these events. The pathological features in-
clude deﬁcient implantation, placental infarction, and microvascular
thrombosis (Greer et al., 2014). The biological plausibility is enhanced
by our knowledge of antiphospholipid syndrome, which is associated
with thrombotic placental damage, and increased thrombin generation.
Antithrombotic therapy guided by a biomarker, antiphospholipid anti-
bodies, is associated with improved pregnancy outcome (Greer et al.,
2014; Empson et al., 2005). In contrast, trials of antithrombotic inter-
vention in unselectedwomen at risk of PMPC, based on outcome of pre-
vious pregnancies, has been found to be ineffective (Greer et al., 2014;
Kaandorp et al., 2010; Clark et al., 2010; Martinelli et al., 2012;
Pasquier et al., 2015; Schleussner et al., 2015). However, an approach
based on stratiﬁcation for a speciﬁc thrombotic process underlying
these PMPC, would be appropriate before discarding such treatment.
This requires a biomarker. One possible biomarker is Annexin–A5
(ANXA5), an anticoagulant protein highly expressed on the apical sur-
faces of syncytiotrophoblasts, ANXA5 prevents coagulation processes
by forming a two dimensional lattice which can be disrupted by
antiphospholipid antibodies (Van Genderen et al., 2008), and has been
reported to promote cell membrane repair in the syncytiotrophoblast
layer (Bouter et al., 2015). The annexin A5 M2 haplotype (ANXA5 M2)
is associated with reduced expression of ANXA5 in placentas from M2
haplotype carriers presenting with PE and FGR (Ota et al., 2013;
Chinni et al., 2009;Markoff et al., 2010). Further, theM2haplotype is as-
sociated with an increased risk of PMPCs: recurrent pregnancy loss
(RPL) (Bogdanova et al., 2007; Tiscia et al., 2009; Miyamura et al.,
2011; Rogenhofer et al., 2012; Tüttelmann et al., 2013; Hock et al.,
2015; Demetriou et al., 2015), FGR (Tiscia et al., 2009) small for gesta-
tional age infants (Tiscia et al., 2012), and gestational hypertension
(Tiscia et al., 2009). The haplotype is transmitted equally by males and
females (Ota et al., 2013; Chinni et al., 2009; Markoff et al., 2010;
Rogenhofer et al., 2012).
In a single study using a murine knockout model, signiﬁcant reduc-
tions both in litter size and fetal weight in ANXA5-null mice (ANXA5-
KO) was reported (Ueki et al., 2012), if accepted this suggests that ma-
ternal expression of ANXA5 in the circulation may be crucial for main-
taining normal pregnancy; further administration of heparin on
pregnancy days 12, 14, 16 and 18 to ANXA5-KO mice signiﬁcantly in-
creased litter size so contributing to the biological plausibility for the
use for heparin for an intervention.
This study investigated, for the ﬁrst time, the pragmatic use of the
maternal and paternal ANXA5 M2 haplotype as a biomarker to stratify
couples at risk of pregnancy failure undergoing assisted conception,
for antithrombotic intervention with low molecular weight heparin
(LMWH).
2. Methods
2.1. Study Population
Three patient cohorts and a retrospective contemporaneous group
of unscreened patients undergoing assisted conception treatment, atﬁve fertility clinics within in the CARE Fertility Group (CFG) were stud-
ied as follows.
• To evaluate the association of the ANXA5haplotype in a retrospective-
ly tested group of 171 females with adverse outcome and 154 of their
partners whose spermwere used. Seventy-seven of these couples had
one or both partners whowere ANXA5M2 positive. These formed the
“Yardstick” reference cohort (N = 77)
• A Randomly selected unscreened retrospective contemporaneous pa-
tient couple group (N = 1000)
• A Prospective, Tested and Treated couple cohort not taken from the
retrospective contemporaneous group (N= 103)
• A matched retrospective control couple cohort (N = 103) selected
from the 1000 retrospective contemporaneous group
Patients were followed until either clinical miscarriage or in live
birth or other pregnancy outcome.
2.2. Yardstick Reference Group
This “Yardstick” reference grouppermitted observation of the timing
of pregnancy losses in untreatedM2 carrier couples. ANXA5M2 screen-
ing was performed in 171 female patients and their partners (17 using
sperm donors were not tested), with at least one failed previous IVF
cycle (mean 1.10). None had achieved a live birth previously, 26% had
a previous miscarriage, and their mean duration of infertility was
4.17 years. There were 77 couples (45%) where one or both partners
were carriers of ANXA5 M2 (two females were egg recipients and
three couples had sperm donation, the donors were not screened).
This group had a similar age to the tested and treated cohort (median
35 range 25–44). The timing of losses in this group were compared to
those of the unscreened, untreated, retrospective contemporaneous
group.
2.3. Retrospective Unscreened Untreated Contemporaneous Group
Of the 1000 couples, 110were egg recipients, 38 were egg share do-
nors. The patients' ages, infertility status and ethnicitywere as described
by Fishel et al. (2014).
2.4. Tested and Treated Cohort
696 patients (369 couples) elected prospectively to be screened for
carriage of the ANXA5 M2 haplotype. The ﬁrst 103 patient couples
found to be ANXA5 M2 positive were enlisted to the cohort and treated
with a prophylactic dose of LMWH on achieving embryo transfer fol-
lowing informed consent, between March 2012 and October 2014. Pa-
tient enlistment was based on their own and their clinician's decision
to test and treat considering their clinical history, which included dura-
tion of infertility, numbers of previous failed cycles and miscarriages.
This was conducted as a clinical practice study with patient information
documents to guide informed consent. Independent counsellingwas of-
fered to all patients.
2.5. Matched Controls
The Tested and Treated cohort was matched with a cohort of 103
retrospective untested and untreated controls drawn from the random-
ly selected group of 1000 unscreened patient couples achieving embryo
transfer with no LMWH treatment. The matching characteristics are
shown in Table 1. None of the treated or control patients had achieved
a live birth previously.
Reporting of this study conforms to the STROBE (The Strengthening
the Reporting of Observational Studies in Epidemiology) statement.
Table 1
Matching variables for Treated and Paired Control patient cohorts.
Tested and
Treated
Matched
controls
(N = 103) (N = 103)
Egg recipients Egg recipient 8 7.8% 8 7.8%
Standard 95 92.2% 95 92.2%
Number of embryos
transferred
1 38 36.9% 38 36.9%
2 64 62.1% 64 62.1%
3 1 1.0% 1 1.0%
Embryo type Cells 1 to 8+ 45 43.7% 45 43.7%
Morula 3 2.9% 3 2.9%
Blastocysts/compacting 55 53.4% 55 53.4%
No aged b/≥35 years b35 34 33.0% 34 33.0%
≥35 69 67.0% 69 67.0%
Age of patient (years) b35: median; (range) 32 (26–34) 32 (22–34)
≥35: median; (range) 38 (35–47) 38 (35–45)
Median; (range) 36 (26–47) 36 (22–45)
Previous failed IVF cycles 0 17 16.5% 26 25.2%
1+ 86 83.5% 77 74.8%
Previous miscarriages 0 53 51.5% 56 54.4%
1+ 50 48.5% 47 45.6%
300 S. Fishel et al. / EBioMedicine 10 (2016) 298–3042.6. Ethical Statement and Informed Consent
Clinic practice and procedures are regulated and routinely inspected
by the Human Fertilisation and Embryology Authority (HFEA), thus the
Internal Review Board (IRB)/external ethical committee are used for
clinical trials and embryo research only. Thiswas a clinical observational
study for a test and treatment regime for recurrent pregnancy loss that
had limited published evidence and as such all CARE medical directors
agreed, following their individual clinical judgement to offer the test
to patients who had full counselling, written detailed information and
signed informed consent based upon patient clinical history. These
forms are available for scrutiny.
2.7. Study Design
The studywas a pragmatic prospective cohort study of LWMH treat-
ment in IVF couples offered screening and found positive for the ANXA5
M2 haplotype, compared to retrospective matched unscreened and un-
treated, couples (controls). No exclusions weremade. The patient char-
acteristics are shown in Table 1. Ovulation induction and embryology
protocols and procedures have been published previously (Fishel et
al., 2011). In the tested and treated group, if either or both of the couple
were carriers of the M2 haplotype, the female received LMWH
(enoxaparin: Clexane; SanoﬁWinthrop, France) subcutaneously in a
dose of 40 mg daily beginning on the day of oocyte retrieval for fresh
embryo transfer or, on the day of frozen embryo transfer, and for amin-
imum of 12 weeks, with the recommendation to continue until term.
Womenwere assessed for TH1/TH2 intracellular cytokine ratio, Nat-
ural Killer cells and HLADQ at the discretion of the treating clinician.
Where the TH1/TH2 intracellular cytokine ratio was disturbed (n =
50), Intralipid® 20% (Fresenius Kabi, New Zealand) was administered
(Kwak–Kim et al., 2013).
2.8. Outcome Measures
The primary outcome measure was the incidence of live birth. Sec-
ondary outcomes were: incidence of implantation, biochemical preg-
nancy loss rate, clinical pregnancy rate, clinical miscarriage rate, live
birth rate outcome by gender and M2 carriage, and allelic dose inﬂu-
ence. Preclinical miscarriage was deﬁned as failure of pregnancy after
a positive biochemical pregnancy test and no fetal heart at ﬁrst ultra-
sound examination at 5–6weeks fromday of embryo transfer; and clin-
ical miscarriage was deﬁned as pregnancy loss after detection of fetal
heart activity.2.9. Genotyping and Quality Control
DNA collection and analysis together with genotyping was per-
formed, by Sanger sequencing as previously described (Fishel et al.,
2014). Puriﬁed amplicons were sequenced using standard conditions
and electrophoresis on an ABI 3730xl DNA analyser.
2.10. Statistical Analysis
Statistical analysiswas independently conducted byQi Statistics Ltd.,
Reading, UK. The analyses included: Mantel-Haenzel chi-squared tests
for trend to assess the statistical signiﬁcance of the association between
i) treatment group and ii) each pregnancy outcome and each of the or-
dinal baseline characteristics. Pearson chi-squared tests for general as-
sociation were used to assess the statistical signiﬁcance of the
association between treatment cohort and of each of the binary and
nominal baseline characteristics, and Fisher's Exact Test was used
where the expected counts were very low. All tests were 2-sided and
statistical signiﬁcance was viewed as accepted if the p-value was b0.05.
2.11. Statistical Software
All analyses were performed in the statistical software package SAS
v9.3 (SAS Institute Inc., 2002–2010). The SAS procedure ‘PROC FREQ’
(Base SAS 9.3 Procedures Guide: Statistical Procedures)was used to per-
form all tests of association (Agresti, 2007). Paired Controls were ran-
domly selected from each matched subgroup by generating random
numbers using the CALL RANUNI subroutine with SAS.
2.12. Independent Variables
In addition to the study cohort (treatment/control), data on the fol-
lowing independent variables were evaluated: patient age (years),
ANXA5 M2 genotyping results (female and male), number of embryos
transferred, stage of embryo development at transfer (1–8 cells morula,
blastocyst), type of incubator (EmbryoscopeTM/standard), duration of
infertility (years), number of previous IVF cycles, number of previous
miscarriages, use of intralipid, donor egg use (egg recipient or egg
share donor).
All data was obtained from the Clinical Information system (CIS)
After 12 weeks clinical miscarriages live births and all other pregnancy
outcomes were reported by the patient in compliance with the
Human Fertility and Embryo Authority (HFEA) requirements.
2.13. Paired Analyses
The matched cohort of 103 paired Controls was drawn from the
1000 retrospective unscreened, untreated contemporaneous couple
group by ﬁnding the number of Tested and Treated and Control patients
that fell into each of the cross-classiﬁcations of baseline characteristics
namely; age, number of embryos transferred, type of embryo trans-
ferred, previous failed miscarriages, previous failed IVF cycles and egg
recipients (a total of 144 possible groups). As this was a pragmatic
study of screening and treatment versus non screening, it is important
to note that a proportion of the controls will be undetected ANXA5
M2 positive. It has previously been estimated that 44% of couples
would be expected to be M2 positive in this IVF population (Fishel et
al., 2014). Thus 1000 patient couples could be expected to include 440
M2 carrier couples (one or both partners' carriers).
3. Results
The yardstick reference group M2 positive couples had poor preg-
nancy outcome with high rates of pregnancy loss at various stages and
no live births. Table 2 shows where in gestation each pregnancy was
lost at each stage up to and including clinical miscarriage, so enabling
Table 2
Pregnancy failures showing where losses occur in untreated groups after embryo transfer.
Unscreened untreated group Unscreened untreated group Yardsticks p-Value
Egg donors and egg recipients Standard Yardstick standard
Unscreened untreated Std vs.
Yardstick Std
(N = 75) (N= 534) (N = 75)
Number of patients with failed live birth after embryo transfer 75 534 75
Number of embryos transferred 106 774 115
Number of embryos with fetal heart activity detected 9 31 12
Implantation incidence (fetal hearts/embryos transferred) 8.5% 4.0% 10.4% 0.0027
Positive pregnancy test 30 88 28
Biochemical pregnancy rate (per patient) 40.0% 16.5% 37.3% b0.0001
Biochemical loss/preclinical miscarriage 23 58 16
Biochemical loss rate 76.7% 65.9% 57.1% 0.4005
Clinical pregnancy 7 30 12
Clinical pregnancy rate 9.3% 5.6% 16.0% 0.0009
Clinical miscarriage 5 30 12
Clinical miscarriage rate 85.7% 100.0% 100.0%
Note: one control egg recipient and one egg donor were lost to follow up after clinical pregnancy and outcome unknown so assumed to have maintained pregnancy.
Note that only patients with an embryo transfer that failed to result in a live birth have been included.
9 control patients with an ectopic pregnancy or termination were excluded.
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retrospective, unscreened, untreated contemporaneous 1000 couple
group.
Excluding egg recipients, the untreated ANXA5M2 carrier Yardstick
group had a statistically higher incidence of implantation, biochemical
and clinical pregnancy than Controls. Their clinical miscarriages all oc-
curred by 12 weeks gestation: two at 6 weeks one at 7 weeks, four at
8 weeks, four at 9 weeks and two at 12 weeks gestation. The incidence
of implantation and clinical pregnancy was signiﬁcantly higher than ei-
ther controls or egg recipients, but patients then lost their clinical preg-
nancies. Thus the untreated M2 carriers have a different pattern of
timing of loss both to the unscreened, untreated standard controls and
to unscreened, untreated egg recipients.
The Tested and Treated cohort, with a potential for more adverse
outcome due to a higher mean maternal age, a greater number ofTable 3
Pregnancy outcome for patients with an embryo transfer.
Study group
Pregnancy outcomes
Tested and
Treated cohort
Contemporaneous ret
unscreened and untre
Patients with an embryo transfer 103 1000
Number of embryos transferred 169 1454
Number of embryos transferred with fetal heart
activity subsequently detected
56 494
Implantation incidence (fetal hearts/embryos
transferred)
33.1% 34.0%
Biochemical pregnancy rate (per patient) 53.4% (N = 55) 50.9% (N = 509)
Biochemical loss rate (per biochemical
pregnancy)
21.8% (N = 12) 15.9% (N = 81)
Clinical pregnancy rate (per patient) 41.7% (N = 43) 42.8% (N = 428)
Patients with clinical miscarriages (miscarriages
after fetal hearts detected)
4 36
Patients with ectopic or terminated clinical
pregnancy
0 9
Clinical miscarriage rate (per clinical
pregnancy)a
9.3% 8.6%
Patients with live births 39 373
Patients lost to follow up/live birth data
unavailable
0 9
Live birth rate (per patient)a,b,c 37.9% 38.5%
a Excludes eight controls with a termination of pregnancy after patients electing to have am
b Note that for the purposes of calculating the Live Birth Rate per patient, nine Control patient
c Includes one live birth (499 g) to a Control patient that was neonatal death.miscarriages, a longer duration of infertility, and more unsuccessful
assisted conception cycles, achieved a live birth rate of 37.9%, compared
to the 1000 retrospective unscreened and untreated group of 38.5%
(Table 3). Statistical analysis showed no signiﬁcant impact of the use
of Embryoscope™ time-lapse incubators and Intralipid (data not
shown but provided in Supplementary Tables). Signiﬁcantly more fa-
vorable outcomes were observed for younger patients, egg recipients
and for thosewhohad blastocysts or two earlier cleavage stage embryos
transferred (data not shown but provided in Supplementary Tables).
The Tested and Treated cohort had a similar outcome to the Paired
Control cohort See Table 4.
Of the four clinical miscarriages in the Tested and Treatment cohort,
one was due to chorionamnionitis at 15 weeks gestation; one was a
twin pregnancy with Dandy Walker variant delivered at 23 weeks,
and two at 12–13 weeks with no diagnosis made.Odds ratio (95% CI) (Treated
cohort/Unscreened untreated)
p-Value (Treated vs.
Unscreened untreated)
rospective
ated group
0.96 (0.69, 1.35) 0.83
1.11 (0.74, 1.66) 0.63
1.47 (0.75, 2.92) 0.26
0.96 (0.63, 1.44) 0.84
1.09 (0.37, 3.23) 0.87
0.97 (0.64, 1.48) 0.89
niocentesis or chorionvillous biopsy and one control with an ectopic pregnancy.
swith Clinical Pregnancywhowere lost to followupwere assumed to have had a live birth.
Table 4
Pregnancy outcome for matched Treated and Paired Control cohorts.
Pregnancy outcomes
Study group
Odds ratio (95% CI) (Treated/Control) p-Value (Treated vs. Control)Tested and Treated Paired Controls
Paired patients with an embryo transfer 103 103
Number of embryos transferred 169 169
Number of embryos transferred with fetal hearts detected 56 51
Implantation incidence (fetal hearts/embryos transferred) 33.1% 30.2% 1.15 (0.72, 1.81) 0.56
Biochemical pregnancy rate (per patient) 53.4% (N = 55) 46.6% (N = 48) 1.31 (0.76, 2.27) 0.33
Biochemical loss rate (per biochemical pregnancy) 21.8% (N = 12) 14.6% (N = 7) 1.63 (0.59, 4.56) 0.35
Clinical pregnancy rate (per patient) 41.7% (N = 43) 39.8% (N = 41) 1.08 (0.62, 1.89) 0.78
Clinical miscarriage rate (per clinical pregnancy) 9.3% (N = 4) 17.1% (N = 7) 0.49 (0.13, 1.85) 0.29
Patients with live births 39 34
Patients lost to follow up/live birth data unavailablea 0 1
Live birth rate (per patient) 37.9% 33.0% 1.24 (0.70, 2.19) 0.47
a 1 patient was lost to follow up in the control cohort after clinical pregnancy at 12 weeks and has been included as a live birth.
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curred at 8, 9, 10, 11, 12, 13 (twins) and 19 weeks respectively with
no diagnosis made. Three of these controls were egg recipients.
Comparing couples with only males who demonstrated carrier or
homozygosity, to couples where only the female had carrier/homozy-
gous status, the live birth outcome is statistically signiﬁcantly different
at the 5% level (p= 0.0452) with 58.3% of male ANXA5M2 only treated
couples having a live birth versus 25.0% of female ANXA5M2 only treat-
ed couples (Table 5). This result is close to the statistically signiﬁcant
cut-off so needs to be interpreted in the context of the size of the differ-
ence and the population.
There is no statistically signiﬁcant evidence of an allelic dose effect
on live birth outcome.4. Discussion
The Yardstick reference group allowed observation of the gestational
stage at which pregnancy losses occur following ET, and demonstrate
the known association (Ota et al., 2013; Markoff et al., 2010; Tiscia et
al., 2009; Rogenhofer et al., 2012) between ANXA5 M2 parental status
and adverse outcome, with higher risk of early clinical pregnancy loss.
The timing of clinical pregnancy loss is consistentwith the previous-
ly reported time of loss in natural pregnancies with ANXA5 M2 carriers
with RPL (Bogdanova et al., 2007; Tiscia et al., 2009; Miyamura et al.,
2011; Tüttelmann et al., 2013; Hock et al., 2015; Demetriou et al., 2015).
The association between parental M2 status and adverse clinical
pregnancy outcomes, coupled with the biological plausibility of the
M2 haplotype operating through procoagulant mechanisms leads to
the hypothesis that the M2 haplotype acts as a biomarker for adverse
pregnancy outcome, which is amenable to intervention with LMWH.
Stratiﬁcation of assisted conception patients by parental ANXA5M2
status would offer targeted intervention with LMWH, delivering a pre-
cision medicine approach.Table 5
Live births for treated patients by carrier status and allelic dose.
All treated patients with complete genetic testing data
Live births
(N = 36) %
C4M2 carrier status Female carrier/homozygote 9 25.0%
Male carrier/homozygote 21 58.3%
Both carrier/homozygote 6 16.7%
Number of alleles 1 29 39.7%
2 to 3 7 30.4%
1 includes: (WT/WT)/(WT/M2); (WT/WT)/(M1/M2); (WT/M2)/(WT/M1); (WT/M2)/(M1/M1
2 includes: (WT/M2)/(WT/M2); (WT/M2)/(M1/M2); (WT/WT)/(M2/M2); (WT/M1)/(M2/M2)
3 includes: (WT/M2)/(M2/M2).
a Seven couples with incomplete genetic testing data have been excluded (ﬁve untested maThe lack of such stratiﬁcation may underlie the inconsistent data
from trials of LMWH for PMPC (Martinelli et al., 2012; Rodger et al.,
2014) due to inclusion of heterogeneous disease mechanisms rather
than a focus on those associated with a procoagulant mechanism.
These ﬁndings also suggest that for LMWH treatment to be effective it
should be introduced before a clinical pregnancy is conﬁrmed, as later
initiation appears too late to improve live birth. The timing of LMWH
administration may also have been a factor in the outcome of trials of
LMWH for recurrent pregnancy loss, where treatmentwas often started
following diagnosis of clinical pregnancy and LMWH was without ben-
eﬁt (Kaandorp et al., 2010; Clark et al., 2010; Pasquier et al., 2015;
Schleussner et al., 2015). The ANXA5 M2 haplotype may also be a rele-
vant biomarker to stratify treatment in a proportion of unexplained in-
fertility and recurrent miscarriage cases and should be explored.
This concept of the parental M2 Haplotype, acting as a biomarker to
stratify assisted conception patients for LMWH therapy, was explored in
the cohort comparison described in this paper. The results of the cohort
comparison show that a tested and treated cohort of ANXA5M2 carriers
do not achieve a signiﬁcantly different live birth rate (37.9%) per em-
bryo transfer cycle both in comparison to a larger, unselected, untreat-
ed, more fertile group and to a paired cohort who would both have a
lower prevalence of M2. Additionally the live birth rate of 37.9% com-
pares favorably to the live birth rate per embryo cycle of 36.1% achieved
from 6572 fresh embryo transfer cycles in CARE patients using their
own eggs in the two years 2013 and 2014. It is further of note that
whereas in 2014 theHFEA reported that themean age ofwomen having
IVF treatment was 35 and their duration of infertility (DOI) was
4 years,67% of the tested and treated cohort in this study were aged
35 and over (median age 38) and had an mean DOI of 5.1 years These
data suggest that screening for ANXA5 M2 haplotype and treatment
with LMWH can improve prognosis for M2 positive couples, to that ex-
pected in a ﬁrst assisted conception cycle in the general population.
The ANXA5 M2 haplotype has been reported to pose an equal risk
whether transmitted paternally or maternally (Ota et al., 2013; ChinniNo live births
Total (N = 96)a p-Value(N = 60) %
26 43.3% 35
23 38.3% 44 0.0452 (Male vs. Female only)
11 18.3% 17
44 60.3% 73 0.4222
16 69.6% 23
).
.
les and two untested females).
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al., 2015). However, the signiﬁcant difference in live birth outcome re-
ported in Table 5 between treated male only carrier couples versus
treated female only carrier couples (p = 0.045) suggests an additional
maternal thrombophilic factor that may further adversely affect preg-
nancy outcome. Ota et al. (Ota et al., 2013) noted that women with re-
current pregnancy loss suffer repeat miscarriages even though the
maternal and paternal ANXA5 M2 haplotype will be transmitted to
the fetus/placenta with a 50% frequency. The possibility that the
ANXA5 M2 haplotype is a thrombophilia is also supported by
Grandone et al. (2010a, b) who reported that deep vein thrombosis in
men and nonpregnant women (Grandone et al., 2010a), and in preg-
nant women (Grandone et al., 2010b) is independently associated
with M2 status. The less favorable outcome for female only carriers or
homozygotes versusmales also suggests that thematernal contribution
is not conﬁned to the transmission of theM2 haplotype to the fetus and
needs further elucidation. There is growing evidence that male factors
are important for abnormal placentation and the development of PE
(Κatsi et al., 2015). The association shown in this study of the paternal
ANXA5 M2 haplotype with adverse outcomes adds weight to the hy-
pothesis that male factors play also play a role in PMPC.
In the cohorts studied, duration of infertility, type of incubator and
the use of intralipid did not have any bearing on pregnancy outcome.
The effect of allelic dose (1 versus 2 or 3 alleles) as reported by
Demetriou et al. (2015) is not observed in this study.
This may be because the allelic dose effect has been reduced by
LMWH treatment.
4.1. Limitations of the Study
Classically for a conﬁrmatory trial it is required to specify upfront the
clinically meaningful difference of interest and then set up the trial to
adequately collect the right amount of data, However, conducting ran-
domized controlled trials in the assisted conception population is inher-
ently difﬁcult as advancing maternal age is associated with a decline in
fertility and such females are reluctant to be randomized. Trials of this
type in naturally-conceived pregnancy require several years to com-
plete, for example the TIPPS trial of antithrombotic intervention for
women with thrombophilia in pregnancy (Rodger et al., 2014) took
12 years. There is further difﬁculty in spontaneous pregnancy if
LMWH is to be introduced early in pregnancy. Given the effect of age
on fertility, the age of the patient cohort, the impact of age on treatment
outcome, and the time required to perform a randomized trial in this
population, a pragmatic approach to screening and treatment was pre-
ferred with rigorous matching of variables. Clark (2013) has suggested
that cohort-controlled are useful in identifying variables associated
with treatment outcomes before proceeding to an RCT. Therefore a
pragmatic approach as described here with a retrospective case control
design is the most practicable ﬁrst step in assessing the hypothesis that
the ANXA5 M2 haplotype is a biomarker for IVF failure, which can be
overcome by treatment with LMWH.
Based on the work of Fishel et al. (2014) the highest incidence we
may estimate for control IVF couples positive for M2 would be 44%;
hence the M2 dilution effect would be at the least a factor of 2.3 (100/
44).
Within the known limitations of the study and the population, how-
ever, no signiﬁcant evidence was found for differences between the
groups in terms of the primary live birth outcome.
4.2. Conclusions
In conclusion, this study suggests that the identiﬁcation and treat-
ment of M2 carrier pregnancies by screening both partners for the M2
haplotype, in assisted reproduction, may identify an adverse prognostic
factor for assisted conception, which can be used to stratify couples for
treatment with LMWH. Such an intervention results in live birthoutcomes similar to those achieved in assisted conception cohorts
with more favorable prognostic factors. This study also suggests that
such treatment should be started prior to clinical pregnancy. In view
of its association with PMPC particularly in the ﬁrst trimester of preg-
nancy, studies on the role of the M2 haplotype are warranted in these
conditions.
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